US Broker Ratings

Harmony Biosciences Holdings, Inc. (HRMY): Investor Outlook Shows 21.82% Upside Potential in Innovative Neurological Treatments

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) presents an intriguing opportunity for investors drawn to the dynamic biotechnology sector, particularly in the niche of neurological disorders. With..

Phreesia, Inc. (PHR) Investor Outlook: 75% Upside Potential According to Analyst Consensus

Phreesia, Inc. (PHR) is capturing investor attention with an impressive analyst consensus that suggests a potential upside of 75.43%. As an integrated SaaS-based software and payment..

GeneDx Holdings Corp. (WGS)

⚠️ No article content returned.

..

Vera Therapeutics, Inc. (VERA) Stock Analysis: Biotechnology Innovator with a 43.84% Potential Upside

Vera Therapeutics, Inc. (NASDAQ: VERA) is making waves in the biotechnology sector as it continues to focus on developing transformative treatments for serious immunological diseases. With..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A High-Growth Biotech with 144.60% Potential Upside

Investors looking for opportunities in the healthcare sector might want to turn their attention to ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). This biotechnology firm, headquartered in San..

Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring the 61.62% Potential Upside for Investors

Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector, operates a vast network of surgical facilities across the United States. Specializing in non-emergency..

Amneal Pharmaceuticals, Inc. (AMRX): Investor Outlook Reveals 8.44% Upside Potential Amid Strong Buy Ratings

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is capturing the attention of investors with its solid market cap of $4.06 billion and a promising potential upside of 8.44%...

Liquidia Corporation (LQDA): Investor Outlook on a Biotech Stock with 26.62% Upside Potential

Liquidia Corporation (NASDAQ: LQDA) has emerged as a compelling option in the biotechnology sector, capturing investor attention with its significant potential upside of 26.62%. With a..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: A Promising 19.67% Upside in the Healthcare Sector

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a notable player in the biopharmaceutical sector, has emerged as a compelling prospect for investors eyeing the healthcare industry. With a..

Indivior PLC (INDV) Stock Analysis: Navigating Growth in the Opioid Treatment Market with a 4.15% Upside

Indivior PLC (NASDAQ: INDV) stands at the forefront of the healthcare sector, specifically within the competitive landscape of specialty drug manufacturing. With a robust market capitalization..

Ascentage Pharma Group Internat (AAPG) Stock Analysis: A 76% Upside Amid Biotech Innovations

Investors with an eye on the biotechnology sector might find Ascentage Pharma Group International (AAPG) an intriguing option, given its potential for significant upside. Despite being..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Biotechnology Innovations and Market Position

Arrowhead Pharmaceuticals, Inc. (ARWR), a prominent player in the biotechnology sector, has captured investor attention with its innovative approach to tackling intractable diseases. With a robust..

Centessa Pharmaceuticals plc (CNTA) Stock Analysis: A Biotech Gem with 56% Upside Potential

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is making waves in the biotechnology sector, capturing investor attention with its promising pipeline and significant upside potential. Headquartered in Altrincham,..

Certara, Inc. (CERT) Stock Analysis: Unlocking a 41.71% Potential Upside with Innovative Biosimulation Solutions

Certara, Inc. (CERT), a leading player in the healthcare sector specializing in health information services, is making waves with its cutting-edge technology-enabled services and software products...

Mesoblast Limited (MESO) Stock Analysis: Unpacking an 84.60% Potential Upside

Mesoblast Limited (NASDAQ: MESO) stands out in the biotechnology sector, not just for its innovative regenerative medicine products but also for the compelling investment opportunities it..

Schrodinger, Inc. (SDGR) Stock Analysis: Harnessing a 52.59% Upside Potential Amidst Rapid Revenue Growth

Schrödinger, Inc. (NASDAQ: SDGR), a trailblazer in the healthcare sector, is reshaping the landscape of drug discovery and materials science with its cutting-edge computational platform. With..

Belite Bio, Inc (BLTE): Analyst Consensus Points to 11.52% Upside Potential in Biotech Innovator

Belite Bio, Inc (NASDAQ: BLTE) is gaining traction in the biotechnology sector with a notable market cap of $6.2 billion. Headquartered in San Diego, California, Belite..

IDEAYA Biosciences (IDYA) Investor Outlook: Exploring a 42.5% Potential Upside in the Precision Oncology Space

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is making waves in the biotechnology sector with its focus on precision medicine and oncology. As a company dedicated to the..

QuidelOrtho Corporation (QDEL) Stock Analysis: Navigating Potential Upside of 28.56% Amidst Market Challenges

QuidelOrtho Corporation (QDEL), a leading name in the healthcare sector specializing in medical devices, offers a compelling case for investors seeking opportunities in the diagnostic testing..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: A 46% Upside Potential Amidst Healthcare Expansion

Acadia Healthcare Company, Inc. (ACHC), a prominent player in the healthcare sector, is drawing significant investor attention with its potential upside of 46.31%. Headquartered in Franklin,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds